Zanubrutinib Better Than Ibrutinib in CLL/SLL? Zanubrutinib Better Than Ibrutinib in CLL/SLL?
An interim phase 3 clinical trial analysis shows encouraging progression-free survival and lower cardiac toxicity in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Clinical Trials | Hematology | Leukemia | Toxicology